论文部分内容阅读
《医学世界报导》1986年2月 Famotidine 快将成为投放市场出售的第三种组胺 H_2-受体阴滞剂。美国食品药品管理局的咨询委员会曾推荐同意该药用来治疗十二指肠溃疡和 Zollinger-Ellison 综合征。
Medical World Report February 1986 Famotidine will soon become the third histamine H 2 -receptor agonist marketed. The Food and Drug Administration’s advisory committee recommended that the drug be used to treat duodenal ulcers and Zollinger-Ellison syndrome.